基础医学与临床 ›› 2017, Vol. 37 ›› Issue (1): 118-122.

• 短篇综述 • 上一篇    下一篇

PI3K/Akt/mTOR信号通路及其相关基因突变与子宫内膜癌靶向性药物治疗的研究进展

曹楚楚,黄炉仁,傅芬   

  1. 南昌大学第二附属医院
  • 收稿日期:2016-02-02 修回日期:2016-05-25 出版日期:2017-01-05 发布日期:2016-12-30
  • 通讯作者: 傅芬 E-mail:fu-fen@163.com
  • 基金资助:
    江西省科技计划

Research advance of PI3K/Akt/mTOR signaling pathway with its related gene mutations and the targeted therapy for endometrial cancer

  • Received:2016-02-02 Revised:2016-05-25 Online:2017-01-05 Published:2016-12-30

摘要: 子宫内膜癌(EC)是最常见的女性生殖道恶性肿瘤之一,其发生发展的分子生物学机制十分复杂。近年来研究发现,磷脂酰肌醇-3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白(PI3K/Akt/mTOR)信号通路调节异常与子宫内膜癌密切相关。PI3K/Akt/mTOR信号通路中的多种受体及激酶的突变和异常激活,可能成为子宫内膜癌治疗的靶点。

关键词: PI3K/Akt/mTOR信号通路, 基因突变, 子宫内膜癌, 靶向治疗

Abstract: Endometrial cancer(EC) is one of the most common gynecological cancer,of which the molecular biological mechanisms is very complex.In recent years, it has been reported that the abnormally regulated PI3K/Akt/mTOR signaling pathway is greatly related with endometrial cancer. The mutation and abnormal activation of the receptors and kinaseof the PI3K/Akt/mTOR signaling pathway may become the therapeutic target of endometrial cancer.

Key words: the PI3K/Akt/mTOR signaling pathway, gene mutations, endometrial cancer, targeted therapy

中图分类号: